You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk

https://doi.org/10.1136/ebm.11.6.178

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr E Barrett-Connor, University of California, San Diego, La Jolla, CA, USA. ebarrettconnor{at}ucsd.edu

    • Source of funding: Eli Lilly.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 191-191 Published Online First: 30 Nov 2006. doi: 10.1136/ebm.11.6.191-a